144 related articles for article (PubMed ID: 11706395)
1. Integration of trastuzumab into adjuvant systemic therapy of breast cancer: ongoing and planned clinical trials.
Hortobagyi GN; Perez EA
Semin Oncol; 2001 Oct; 28(5 Suppl 16):41-6. PubMed ID: 11706395
[TBL] [Abstract][Full Text] [Related]
2. Ongoing and planned adjuvant trials with trastuzumab.
Perez EA; Hortobagyi GN
Semin Oncol; 2000 Dec; 27(6 Suppl 11):26-32; discussion 92-100. PubMed ID: 11236024
[TBL] [Abstract][Full Text] [Related]
3. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
Slamon D; Pegram M
Semin Oncol; 2001 Feb; 28(1 Suppl 3):13-9. PubMed ID: 11301370
[TBL] [Abstract][Full Text] [Related]
4. Future directions in the adjuvant treatment of breast cancer: the role of trastuzumab.
Smith I
Ann Oncol; 2001; 12 Suppl 1():S75-9. PubMed ID: 11521726
[TBL] [Abstract][Full Text] [Related]
5. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
Baselga J
Oncology; 2001; 61 Suppl 2():14-21. PubMed ID: 11694783
[TBL] [Abstract][Full Text] [Related]
6. Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.
Pegram MD; O'Callaghan C
Clin Breast Cancer; 2001 Oct; 2 Suppl 1():S15-9. PubMed ID: 11970740
[TBL] [Abstract][Full Text] [Related]
7. High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer.
Paluch-Shimon S; Wolf I; Goldberg H; Evron E; Papa MZ; Shabtai M; Barsuk D; Yosepovich A; Modiano T; Catane R; Kaufman B
Acta Oncol; 2008; 47(8):1564-9. PubMed ID: 18607846
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
McKeage K; Perry CM
Drugs; 2002; 62(1):209-43. PubMed ID: 11790161
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant trastuzumab therapy for HER2-positive breast cancer.
Jahanzeb M
Clin Breast Cancer; 2008 Aug; 8(4):324-33. PubMed ID: 18757259
[TBL] [Abstract][Full Text] [Related]
10. HER2 overexpressing metastatic breast cancer.
Spigel DR; Burstein HJ
Curr Treat Options Oncol; 2002 Apr; 3(2):163-74. PubMed ID: 12057079
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
12. New adjuvant strategies for breast cancer: meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin).
Nabholtz JM; Slamon D
Semin Oncol; 2001 Feb; 28(1 Suppl 3):1-12. PubMed ID: 11301369
[TBL] [Abstract][Full Text] [Related]
13. [Combined chemotherapy with molecular-targeted agent for breast cancer].
Ito Y; Miura H
Gan To Kagaku Ryoho; 2008 May; 35(5):731-6. PubMed ID: 18487908
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer.
Burris HA
Semin Oncol; 2001 Feb; 28(1 Suppl 3):38-44. PubMed ID: 11301373
[TBL] [Abstract][Full Text] [Related]
15. Moving forward: Herceptin in the adjuvant setting.
Tan-Chiu E; Piccart M
Oncology; 2002; 63 Suppl 1():57-63. PubMed ID: 12422056
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with trastuzumab (herceptin).
Vogel CL; Franco SX
Breast J; 2003; 9(6):452-62. PubMed ID: 14616939
[TBL] [Abstract][Full Text] [Related]
17. Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology.
De Laurentiis M; Cancello G; Zinno L; Montagna E; Malorni L; Esposito A; Pennacchio R; Silvestro L; Giuliano M; Giordano A; Caputo F; Accurso A; De Placido S
Ann Oncol; 2005 May; 16 Suppl 4():iv7-13. PubMed ID: 15923434
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.
Del Mastro L; Lambertini M; Bighin C; Levaggi A; D'Alonzo A; Giraudi S; Pronzato P
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1391-405. PubMed ID: 23072512
[TBL] [Abstract][Full Text] [Related]
19. Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy.
Crown J; Pegram M
Breast Cancer Res Treat; 2003; 79 Suppl 1():S11-8. PubMed ID: 12868801
[TBL] [Abstract][Full Text] [Related]
20. An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel. Breast Cancer Medicine Service.
Gilewski T; Seidman A; Norton L; Hudis C
Cancer Chemother Pharmacol; 2000; 46 Suppl():S23-6. PubMed ID: 10950143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
